<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="14d86267-3396-4311-9f0b-64fe41fbb8cb"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <effectiveTime value="20100407"/>
   <setId root="4b5513c3-b57f-46f1-9855-dad1063aa4c9"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="194123980" root="1.3.6.1.4.1.519.1"/>
            <name>Physicians Total Care, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="194123980" root="1.3.6.1.4.1.519.1"/>
                        <name>Physicians Total Care, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="repack"/>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="relabel"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="a1a3d166-a636-4f6d-8dee-713d98b41983"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL listing data elements section"/>
               <effectiveTime value="20110316"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54868-4135" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Etodolac<suffix/>
                        </name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>etodolac</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="51672-4017" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="300" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2M36281008" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETODOLAC</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2M36281008" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ETODOLAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8PJ61P6TS3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC	</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-4135-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-4135-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100331"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075078" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="pink" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">ETO;200;MG</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54868-5274" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Etodolac<suffix/>
                        </name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>etodolac</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="51672-4016" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="200" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2M36281008" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETODOLAC</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2M36281008" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ETODOLAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PN2ZH5LOQY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 3</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8PJ61P6TS3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5274-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5274-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5274-2" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5274-3" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20050427"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075078" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="pink" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">ETO;200;MG</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54868-3955" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Etodolac<suffix/>
                        </name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>etodolac</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="51672-4018" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="400" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2M36281008" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETODOLAC</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2M36281008" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ETODOLAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-3955-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-3955-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-3955-2" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="120" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-3955-3" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-3955-4" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20000117"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075074" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="pink" xsi:type="CE">
                              <originalText>Peach</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">T88</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54868-4059" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Etodolac<suffix/>
                        </name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>etodolac</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="51672-4036" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="500" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2M36281008" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETODOLAC</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2M36281008" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ETODOLAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="35SW5USQ3G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C YELLOW NO. 10</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-4059-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-4059-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-4059-2" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-4059-3" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19990421"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075074" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">TARO;89</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="ac6df22d-2d3e-4ef3-ace6-5b3d2c263244"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
               </text>
               <effectiveTime value="20100407"/>
            </section>
         </component>
         <component>
            <section>
               <id root="66e10f8c-83e9-4bdc-ae9e-026eddac31f2"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <text>
                  <linkHtml href=""/>Cardiovascular Risk<list listType="unordered" ID="i43df71cd-1774-47fd-823e-d98d48983a97">
                     <item>NSAIDs may cause an increased risk of serious cardiovascular thrombotic 
events, myocardial infarction (MI), and stroke, which can be fatal. This risk 
may increase with duration of use. Patients with cardiovascular disease or risk 
factors for cardiovascular disease may be at greater risk. (See <content styleCode="bold">
                           <linkHtml href="#Warnings">WARNINGS</linkHtml>
                        </content>).</item>
                     <item>Etodolac capsules USP, 200 mg and 300 mg, and Etodolac tablets USP, 400 mg 
and 500 mg are contraindicated for the treatment of peri-operative pain in the 
setting of coronary artery bypass graft (CABG) surgery (See <content styleCode="bold">
                           <linkHtml href="#Warnings">WARNINGS</linkHtml>
                        </content>).</item>
                  </list>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Gastrointestinal Risk<list listType="unordered" ID="i590df184-25ff-461b-84af-3a7af7ae300d">
                     <item>NSAIDs cause an increased risk of serious gastrointestinal adverse events 
including bleeding, ulceration, and perforation of the stomach or intestines, 
which can be fatal. These events can occur at any time during use and without 
warning symptoms. Elderly patients are at greater risk for serious 
gastrointestinal (GI) events. (See <content styleCode="bold">
                           <linkHtml href="#Warnings">WARNINGS</linkHtml>
                        </content>).</item>
                  </list>
               </text>
               <effectiveTime value="20100407"/>
            </section>
         </component>
         <component>
            <section>
               <id root="3e39fcc9-444a-4319-8948-d185d10d831c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Etodolac capsules and tablets, USP are members of the 
pyranocarboxylic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). 
Each tablet and capsule contains etodolac for oral administration. Etodolac is a 
racemic mixture of [+]S and [-]R-enantiomers. Etodolac is a white crystalline 
compound, insoluble in water but soluble in alcohols, chloroform, dimethyl 
sulfoxide, and aqueous polyethylene glycol.</paragraph>The chemical name is () 
1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid. The molecular 
weight of the base is 287.37. It has a pKa of 4.65 and an n-octanol: water 
partition coefficient of 11.4 at pH 7.4. The molecular formula for etodolac is 
C<sub>17</sub>H<sub>21</sub>NO<sub>3</sub>, 
and it has the following structural formula:<renderMultiMedia referencedObject="MM1"/>
                  <paragraph>
                     <content styleCode="italics">Each Capsule, for oral administration, contains 200 or 
300 mg of Etodolac. In addition, each capsule contains the following inactive 
ingredients:</content> Ammonium Hydroxide USP, Black Iron Oxide USP, Colloidal 
Silicone Dioxide NF, Erythrosine (200 mg only), Ethyl Alcohol USP, Gelatin, 
Isopropyl Alcohol USP, Lactose Monohydrate NF, Magnesium Stearate NF, 
Microcrystalline Cellulose NF, N-Butyl Alcohol USP, Povidone USP, Propylene 
Glycol USP, Purified Water USP, Shellac, Titanium Dioxide.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Each Tablet, for oral administration, contains 400 mg or 
500 mg of Etodolac. In addition, each tablet contains the following inactive 
ingredients:</content> Hydroxypropyl Methylcellulose 2910 USP, Lactose Monohydrate 
NF, Magnesium Stearate, Microcrystalline Cellulose NF, Povidone USP, and Sodium 
Starch Glycolate NF. Also, each 400 mg tablet contains Iron Oxide Red, Iron 
Oxide Yellow, Polyethylene Glycol 400 NF, and Titanium Dioxide. Each 500 mg 
tablet contains Opadry Oy Blue (FD + C Blue #1 Aluminum Lake and D + C Yellow 
#10).</paragraph>
               </text>
               <effectiveTime value="20100407"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM1">
                     <text>image of chemical structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="chemical structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="bb204064-f0cb-4dfc-85f1-54073ae375e5"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <linkHtml href="#section-"/>Pharmacodynamics<paragraph>Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) that 
exhibits anti-inflammatory, analgesic, and antipyretic activities in animal 
models. The mechanism of action of etodolac, like that of other NSAIDs, is not 
completely understood, but may be related to the prostaglandin synthetase 
inhibition.</paragraph>
                  <paragraph>Etodolac is a racemic mixture of [-]R- and [+]S-etodolac. As with other 
NSAIDs, it has been demonstrated in animals that the [+]S-form is biologically 
active. Both enantiomers are stable and there is no [-]R to [+]S conversion 
<content styleCode="italics">in vivo</content>.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>Pharmacokinetics<linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>Absorption<paragraph>The systemic bioavailability of etodolac from etodolac capsules 
and tablets, USP is 100% as compared to solution and at least 80% as determined 
from mass balance studies. Etodolac is well absorbed and had a relative 
bioavailability of 100% when 200 mg capsules were compared with a solution of 
etodolac. Based on mass balance studies, the systemic availability of etodolac 
from either the tablet or capsule formulation is at least 80%. Etodolac does not 
undergo significant first-pass metabolism following oral administration. Mean ( 
1 SD) peak plasma concentrations (C<sub>max</sub>) range from 
approximately 14  4 to 37  9 g/mL after 200 to 600 mg single doses and are 
reached in 80  30 minutes (see <linkHtml href="#section-">    Table 1</linkHtml> for summary of 
pharmacokinetic parameters). The dose-proportionality based on the area under 
the plasma concentration-time curve (AUC) is linear following doses up to 600 mg 
every 12 hours. Peak concentrations are dose proportional for both total and 
free etodolac following doses up to 400 mg every 12 hours, but following a 600 
mg dose, the peak is about 20% higher than predicted on the basis of lower 
doses. The extent of absorption of etodolac is not affected when etodolac 
tablets or capsules are administered after a meal. Food intake, however, reduces 
the peak concentration reached by approximately one-half and increases the time 
to peak concentration by 1.4 to 3.8 hours.</paragraph>
                  <table ID="i17f8380c-a0b9-4871-8bfc-f98dd35a1517" width="100%">
                     <caption>Table 1. Mean (CV%)* Pharmacokinetic Parameters of etodolac in Normal Healthy Adults and Various Special Populations</caption>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">PK <br/>Parameters</content>
                           </td>
                           <td>
                              <content styleCode="bold">Normal <br/>Healthy <br/>Adults<br/>(18-65)<linkHtml href="#section-"> </linkHtml>
                                 <br/>(n=179)</content>
                           </td>
                           <td>
                              <content styleCode="bold">Healthy <br/>Males<br/>(18-65)<br/>
                                 <br/>(n=176)</content>
                           </td>
                           <td>
                              <content styleCode="bold">Healthy <br/>Females<br/>(27-65)<br/>
                                 <br/>(n=3)</content>
                           </td>
                           <td>
                              <content styleCode="bold">Elderly<br/>(&gt;65)<br/>(70-84)<br/>
                                 <br/>
                                 <br/>
                              </content>
                           </td>
                           <td>
                              <content styleCode="bold">Hemodialysis<br/>(n=9)<br/>
                                 <br/>
                                 <br/>
                              </content>
                              <content styleCode="bold">Dialysis On</content>
                           </td>
                           <td>
                              <content styleCode="bold">(24-65)<br/>Dialysis<br/>
                                 <br/>
                                 <br/>
                              </content>
                              <content styleCode="bold">Dialysis Off</content>
                           </td>
                           <td>
                              <content styleCode="bold">Renal <br/>Impairment<br/>(46-73)<br/>
                                 <br/>(n=10)</content>
                           </td>
                           <td>
                              <content styleCode="bold">Hepatic <br/>Impairment<br/>(34-60)<br/>
                                 <br/>(n=9)</content>
                           </td>
                        </tr>
                        <tr>
                           <td>T<sub>max,</sub>h</td>
                           <td>1.4<br/>(61%)<linkHtml href="#section-"> *</linkHtml>
                           </td>
                           <td>1.4<br/>(60%)</td>
                           <td>1.7<br/>(60%)</td>
                           <td>1.2<br/>(43%)</td>
                           <td>1.7<br/>(88%)</td>
                           <td>0.9<br/>(67%)</td>
                           <td>2.1<br/>(46%)</td>
                           <td>1.1<br/>(15%)</td>
                        </tr>
                        <tr>
                           <td>Oral <br/>Clearance, <br/>mL/h/kg <br/>(CL/F)</td>
                           <td>49.1<br/>(33%)</td>
                           <td>49.4<br/>(33%)</td>
                           <td>35.7<br/>(28%)</td>
                           <td>45.7<br/>(27%)</td>
                           <td>NA<br/>
                           </td>
                           <td>NA<br/>
                           </td>
                           <td>58.3<br/>(19%)</td>
                           <td>42.0<br/>(43%)</td>
                        </tr>
                        <tr>
                           <td>Apparent <br/>Volume of <br/>Distribution, <br/>mL/kg (Vd/F)</td>
                           <td>393<br/>(29%)</td>
                           <td>394<br/>(29%)</td>
                           <td>300<br/>(8%)</td>
                           <td>414<br/>(38%)</td>
                           <td>NA<br/>
                           </td>
                           <td>NA<br/>
                           </td>
                           <td>NA<br/>
                           </td>
                           <td>NA<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Terminal Half<br/>-Life, h</td>
                           <td>6.4<br/>(22%)</td>
                           <td>6.4<br/>(22%)</td>
                           <td>7.9<br/>(35%)</td>
                           <td>6.5<br/>(24%)</td>
                           <td>5.1<br/>(22%)</td>
                           <td>7.5<br/>(34%)</td>
                           <td>NA<br/>
                           </td>
                           <td>5.7<br/>(24%)</td>
                        </tr>
                     </tbody>
                  </table>NA = not available<br/>
                  <linkHtml href="#section-">   *</linkHtml> % Coefficient of variation<br/>
                  <linkHtml href="#section-">   </linkHtml> Age Range (years)<br/>
                  <br/>
                  <br/>
                  <br/>
                  <linkHtml href="#section-"/>Distribution<paragraph>The mean apparent volume of distribution (Vd/F) of etodolac is 
approximately 390 mL/kg. Etodolac is more than 99% bound to plasma proteins, 
primarily to albumin. The free fraction is less than 1% and is independent of 
etodolac total concentration over the dose range studied. It is not known 
whether etodolac is excreted in human milk; however, based on its 
physical-chemical properties, excretion into breast milk is expected. Data from 
<content styleCode="italics">in vitro</content> studies, using peak serum concentrations at 
reported therapeutic doses in humans, show that the etodolac free fraction is 
not significantly altered by acetaminophen, ibuprofen, indomethacin, naproxen, 
piroxicam, chlorpropamide, glipizide, glyburide, phenytoin, and 
probenecid.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>Metabolism<paragraph>Etodolac is extensively metabolized in the liver. The role, if 
any, of a specific cytochrome P450 system in the metabolism of etodolac is 
unknown. Several etodolac metabolites have been identified in human plasma and 
urine. Other metabolites remain to be identified. The metabolites include 6-, 
7-, and 8- hydroxylated-etodolac and etodolac glucuronide. After a single dose 
of 14C-etodolac, hydroxylated metabolites accounted for less than 10% of total 
drug in serum. On chronic dosing, hydroxylated-etodolac metabolite does not 
accumulate in the plasma of patients with normal renal function. The extent of 
accumulation of hydroxylated-etodolac metabolites in patients with renal 
dysfunction has not been studied. The hydroxylated-etodolac metabolites undergo 
further glucuronidation followed by renal excretion and partial elimination in 
the feces.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>Excretion<paragraph>The mean oral clearance of etodolac following oral dosing is 49 
( 16) mL/h/kg. Approximately 1% of an etodolac dose is excreted unchanged in 
the urine with 72% of the dose excreted into urine as parent drug plus 
metabolite:</paragraph>
                  <table width="80%" ID="i228b0b90-4ece-4fe7-8d87-cfb6f4c1ae52">
                     <tbody>
                        <tr>
                           <td>-etodolac, unchanged</td>
                           <td>1%<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>-etodolac glucuronide</td>
                           <td>13%<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>-hydroxylated metabolites (6-, 7-, and 8-OH)</td>
                           <td>5%<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>-hydroxylated metabolite glucuronides</td>
                           <td>20%<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>-unidentified metabolites</td>
                           <td>33%<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Although renal elimination is a significant pathway of excretion for etodolac 
metabolites, no dosing adjustment in patients with mild to moderate renal 
dysfunction is generally necessary. The terminal half-life (t<sub>1/2</sub>) of etodolac is 6.4 hours (22% CV). In patients with severe 
renal dysfunction or undergoing hemodialysis, dosing adjustment is not generally 
necessary.</paragraph>
                  <paragraph>Fecal excretion accounted for 16% of the dose.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>Special Populations<linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>Geriatric<paragraph>In etodolac clinical studies, no overall differences in safety or 
effectiveness were observed between these patients and younger patients. In 
pharmacokinetic studies, age was shown not to have any effect on etodolac 
half-life or protein binding, and there was no change in expected drug 
accumulation. Therefore no dosage adjustment is generally necessary in the 
elderly on the basis of pharmacokinetics (see <content styleCode="bold">
                        <linkHtml href="#section-"> PRECAUTIONS, Geriatric Use</linkHtml>
                     </content>).</paragraph>
                  <paragraph>Etodolac is eliminated primarily by the kidney. Because elderly patients are 
more likely to have decreased renal function, care should be taken in dose 
selection, and it may be useful to monitor renal function (see <content styleCode="bold">
                        <linkHtml href="#section-"> WARNINGS, Renal Effects</linkHtml>
                     </content>).</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>Pediatric<paragraph>Safety and effectiveness in pediatric patients below the age of 
18 years have not been established.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>Race<paragraph>Pharmacokinetic differences due to race have not been identified. 
Clinical studies included patients of many races, all of whom responded in a 
similar fashion.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>Hepatic Insufficiency<paragraph>Etodolac is predominantly metabolized by the liver. In patients 
with compensated hepatic cirrhosis, the disposition of total and free etodolac 
is not altered. Patients with acute and chronic hepatic diseases do not 
generally require reduced doses of etodolac compared to patients with normal 
hepatic function. However, etodolac clearance is dependent on liver function and 
could be reduced in patients with severe hepatic failure. Etodolac plasma 
protein binding did not change in patients with compensated hepatic cirrhosis 
given etodolac.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>Renal Insufficiency<paragraph>Etodolac pharmacokinetics have been investigated in subjects with 
renal insufficiency. Etodolac renal clearance was unchanged in the presence of 
mild-to-moderate renal failure (creatinine clearance 37 to 88 mL/min). 
Furthermore, there were no significant differences in the disposition of total 
and free etodolac in these patients. However, etodolac should be used with 
caution in such patients because, as with other NSAIDs, it may further decrease 
renal function in some patients. In patients undergoing hemodialysis, there was 
a 50% greater apparent clearance of total etodolac, due to a 50% greater unbound 
fraction. Free etodolac clearance was not altered, indicating the importance of 
protein binding in etodolac's disposition. Etodolac is not significantly removed 
from the blood in patients undergoing hemodialysis.</paragraph>
               </text>
               <effectiveTime value="20100407"/>
            </section>
         </component>
         <component>
            <section>
               <id root="40a3006a-9d2e-47e2-aaa2-9a9698fafbd8"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>CLINICAL TRIALS</title>
               <text>
                  <linkHtml href=""/>Analgesia<paragraph>Controlled clinical trials in analgesia were single-dose, 
randomized, double-blind, parallel studies in three pain models, including 
dental extractions. The analgesic effective dose for etodolac established in 
these acute pain models was 200 to 400 mg. The onset of analgesia occurred 
approximately 30 minutes after oral administration. Etodolac 200 mg provided 
efficacy comparable to that obtained with aspirin (650 mg). Etodolac 400 mg 
provided efficacy comparable to that obtained with acetaminophen with codeine 
(600 mg + 60 mg). The peak analgesic effect was between 1 to 2 hours. Duration 
of relief averaged 4 to 5 hours for 200 mg of etodolac and 5 to 6 hours for 400 
mg of etodolac as measured by when approximately half of the patients required 
remedication.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Osteoarthritis<paragraph>The use of etodolac in managing the signs and symptoms of 
osteoarthritis of the hip or knee was assessed in double-blind, randomized, 
controlled clinical trials in 341 patients. In patients with osteoarthritis of 
the knee, etodolac, in doses of 600 to 1000 mg/day, was better than placebo in 
two studies. The clinical trials in osteoarthritis used b.i.d. dosage 
regimens.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Rheumatoid Arthritis<paragraph>In a 3-month study with 426 patients, etodolac 300 mg b.i.d. was 
effective in management of rheumatoid arthritis and comparable in efficacy to 
piroxicam 20 mg/day. In a long-term study with 1,446 patients in which 60% of 
patients completed 6 months of therapy and 20% completed 3 years of therapy, 
etodolac in a dose of 500 mg b.i.d. provided efficacy comparable to that 
obtained with ibuprofen 600 mg q.i.d. In clinical trials of rheumatoid arthritis 
patients, etodolac has been used in combination with gold, d-penicillamine, 
chloroquine, corticosteroids, and methotrexate.</paragraph>
               </text>
               <effectiveTime value="20100407"/>
            </section>
         </component>
         <component>
            <section>
               <id root="d7f306d5-e591-4d6b-b9e4-5c379e8206bf"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Carefully consider the potential benefits and risks of etodolac 
capsules and tablets, USP, and other treatment options before deciding to use 
etodolac capsules and tablets, USP. Use the lowest effective dose for the 
shortest duration consistent with individual patient treatment goals (see <content styleCode="bold">
                        <linkHtml href="#Warnings">WARNINGS</linkHtml>
                     </content>).</paragraph>
                  <paragraph>Etodolac Capsules and Tablets, USP are indicated:</paragraph>
                  <list listType="unordered" ID="ibe90aa41-bd91-4c6d-8225-56fff146447d">
                     <item>For acute and long-term use in the management of signs and symptoms of the 
following: 
<list listType="ordered" ID="i9feee730-63a4-496a-862e-59dc6ed96fd9">
                           <item>Osteoarthritis</item>
                           <item>Rheumatoid arthritis</item>
                        </list>
                     </item>
                     <item>For the management of acute pain</item>
                  </list>
               </text>
               <effectiveTime value="20100407"/>
            </section>
         </component>
         <component>
            <section>
               <id root="28d8555d-1258-499e-a591-b77ba245d471"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Etodolac Capsules and Tablets, USP are contraindicated in 
patients with known hypersensitivity to etodolac or other ingredients in 
etodolac.</paragraph>
                  <paragraph>Etodolac Capsules and Tablets, USP should not be given to patients who have 
experienced asthma, urticaria, or other allergic-type reactions after taking 
aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to 
NSAIDs have been reported in such patients (see <content styleCode="bold">
                        <linkHtml href="#WarnAR">WARNINGS, Anaphylactoid Reactions</linkHtml>
                     </content> and <content styleCode="bold">
                        <linkHtml href="#PreAsthma">PRECAUTIONS, Pre-existing 
Asthma</linkHtml>
                     </content>).</paragraph>
                  <paragraph>Etodolac capsules and tablets, USP are contraindicated for the treatment of 
peri-operative pain in the setting of coronary artery bypass graft (CABG) 
surgery (see <content styleCode="bold">
                        <linkHtml href="#Warnings">WARNINGS</linkHtml>
                     </content>).</paragraph>
               </text>
               <effectiveTime value="20100407"/>
            </section>
         </component>
         <component>
            <section>
               <id root="76c22d21-8c6e-4277-ad1e-b62845413b84"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <linkHtml href=""/>CARDIOVASCULAR EFFECTS<linkHtml href=""/>
                  <linkHtml href=""/>Cardiovascular Thrombotic Events<paragraph>Clinical trials of several COX-2 selective and nonselective 
NSAIDs of up to three years duration have shown an increased risk of serious 
cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which 
can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a 
similar risk. Patients with known CV disease or risk factors for CV disease may 
be at greater risk. To minimize the potential risk for an adverse CV event in 
patients treated with an NSAID, the lowest effective dose should be used for the 
shortest duration possible. Physicians and patients should remain alert for the 
development of such events, even in the absence of previous CV symptoms. 
Patients should be informed about the signs and/or symptoms of serious CV events 
and the steps to take if they occur.</paragraph>
                  <paragraph>There is no consistent evidence that concurrent use of aspirin mitigates the 
increased risk of serious CV thrombotic events associated with NSAID use. The 
concurrent use of aspirin and an NSAID does increase the risk of serious GI 
events (see <content styleCode="bold">
                        <linkHtml href="#WarnGE">WARNINGS, Gastrointestinal 
Effects - Risk of Ulceration, Bleeding, and Perforation</linkHtml>
                     </content>).</paragraph>
                  <paragraph>Two large, controlled, clinical trials of a COX-2 selective NSAID for the 
treatment of pain in the first 10-14 days following CABG surgery found an 
increased incidence of myocardial infarction and stroke (see <content styleCode="bold">
                        <linkHtml href="#CONTRAINDICATIONS">CONTRAINDICATIONS</linkHtml>
                     </content>).</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Hypertension<paragraph>NSAIDs, including etodolac capsules and tablets, USP, can lead to 
onset of new hypertension or worsening of pre-existing hypertension, either of 
which may contribute to the increased incidence of CV events. Patients taking 
thiazides or loop diuretics may have impaired response to these therapies when 
taking NSAIDs. NSAIDs, including etodolac capsules and tablets,USP, should be 
used with caution in patients with hypertension. Blood pressure (BP) should be 
monitored closely during the initiation of NSAID treatment and throughout the 
course of therapy.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Congestive Heart Failure and Edema<paragraph>Fluid retention and edema have been observed in some patients 
taking NSAIDs. Etodolac capsules and tablets, USP should be used with caution in 
patients with fluid retention or heart failure.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Gastrointestinal Effects - Risk of Ulceration, 
Bleeding, and Perforation<paragraph>NSAIDs, including etodolac capsules and tablets, USP, can cause 
serious gastrointestinal (GI) adverse events including inflammation, bleeding, 
ulceration, and perforation of the stomach, small intestine or large intestine, 
which can be fatal. These serious adverse events can occur at any time, with or 
without warning symptoms, in patients treated with NSAIDs. Only one in five 
patients, who develop a serious upper GI adverse event on NSAID therapy, is 
symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs 
occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% 
of patients treated for one year. These trends continue with longer duration of 
use, increasing the likelihood of developing a serious GI event at some time 
during the course of therapy. However, even short-term therapy is not without 
risk. Physicians should inform patients about the signs and/or symptoms of 
serious GI toxicity and what steps to take if they occur.</paragraph>
                  <paragraph>NSAIDs should be prescribed with extreme caution in those with a prior 
history of ulcer disease or gastrointestinal bleeding. Patients with a <content styleCode="italics">prior history of peptic ulcer disease, and/or gastrointestinal 
bleeding</content>, and who use NSAIDs have a greater than 10-fold increased risk 
for developing a GI bleed compared to patients with neither of these risk 
factors. Other factors that increase the risk for GI bleeding in patients 
treated with NSAIDs include concomitant use of oral corticosteroids or 
anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older 
age, and poor general health status. Most spontaneous reports of fatal GI events 
are in elderly or debilitated patients, and therefore, special care should be 
taken in treating this population.</paragraph>
                  <paragraph>To minimize the potential risk for an adverse GI event in patients treated 
with an NSAID, the lowest effective dose should be used for the shortest 
possible duration. Patients and physicians should remain alert for signs and 
symptoms of GI ulceration and bleeding during NSAID therapy and promptly 
initiate additional evaluation and treatment if a serious GI adverse event is 
suspected. This should include discontinuation of the NSAID until a serious GI 
adverse event is ruled out. For high risk patients, alternate therapies that do 
not involve NSAIDs should be considered.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Renal Effects<paragraph>Long-term administration of NSAIDs has resulted in renal 
papillary necrosis and other renal injury. Renal toxicity has also been seen in 
patients in whom renal prostaglandins have a compensatory role in the 
maintenance of renal perfusion. In these patients, administration of a 
nonsteroidal antiinflammatory drug may cause a dose-dependent reduction in 
prostaglandin formation and, secondarily, in renal blood flow, which may 
precipitate overt renal decompensation. Patients at greater risk of this 
reaction are those with impaired renal function, heart failure, liver 
dysfunction, those taking diuretics and ACE inhibitors, and the elderly. 
Discontinuation of NSAID therapy is usually followed by recovery to the 
pretreatment state.</paragraph>
                  <paragraph>Renal pelvic transitional epithelial hyperplasia, a spontaneous change 
occurring with variable frequency, was observed with increased frequency in 
treated male rats in a 2-year chronic study.</paragraph>
                  <paragraph>Caution is recommended in patients with pre-existing kidney disease.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Advanced Renal Disease<paragraph>No information is available from controlled clinical studies 
regarding the use of etodolac capsules and tablets, USP, in patients with 
advanced renal disease. Therefore, treatment with etodolac capsules and tablets, 
USP is not recommended in these patients with advanced renal disease. If 
etodolac capsules and tablets, USP therapy must be initiated, close monitoring 
of the patient's renal function is advisable.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Anaphylactoid Reactions<paragraph>As with other NSAIDs, anaphylactoid reactions may occur in 
patients without prior exposure to etodolac capsules and tablets, USP. Etodolac 
capsules and tablets, USP should not be given to patients with the aspirin 
triad. This symptom complex typically occurs in asthmatic patients who 
experience rhinitis with or without nasal polyps, or who exhibit severe, 
potentially fatal bronchospasm after taking aspirin or other NSAIDs. Fatal 
reactions have been reported in such patients (see <content styleCode="bold">
                        <linkHtml href="#CONTRAINDICATIONS">CONTRAINDICATIONS</linkHtml>
                     </content> and <content styleCode="bold">
                        <linkHtml href="#PreAsthma">PRECAUTIONS, General, Pre-existing Asthma</linkHtml>
                     </content>). 
Emergency help should be sought in cases where an anaphylactoid reaction 
occurs.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Skin Reactions<paragraph>NSAIDs, including etodolac capsules and tablets, USP, can cause 
serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson 
Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These 
serious events may occur without warning. Patients should be informed about the 
signs and symptoms of serious skin manifestations and use of the drug should be 
discontinued at the first appearance of skin rash or any other sign of 
hypersensitivity.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Pregnancy<paragraph>In late pregnancy, the third trimester, as with other NSAIDs, 
etodolac capsules and tablets, USP should be avoided because it may cause 
premature closure of the ductus arteriosus (see <content styleCode="bold">
                        <linkHtml href="#PreNE">PRECAUTIONS, Pregnancy, Nonteratogenic Effects</linkHtml>
                     </content>).</paragraph>
               </text>
               <effectiveTime value="20100407"/>
            </section>
         </component>
         <component>
            <section>
               <id root="af5a14e4-c9b3-456d-9871-a281761abf9f"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text>
                  <linkHtml href=""/>General<paragraph>Etodolac capsules and tablets, USP cannot be expected to 
substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt 
discontinuation of corticosteroids may lead to disease exacerbation. Patients on 
prolonged corticosteroid therapy should have their therapy tapered solely if a 
decision is made to discontinue corticosteroids.</paragraph>
                  <paragraph>The pharmacological activity of etodolac capsules and tablets, USP in 
reducing fever and inflammation may diminish the utility of these diagnostic 
signs in detecting complications of presumed noninfectious, painful 
conditions.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Hepatic Effects<paragraph>Borderline elevations of one or more liver tests may occur in up 
to 15% of patients taking NSAIDs including etodolac capsules and tablets, USP. 
These laboratory abnormalities may progress, may remain unchanged, or may be 
transient with continuing therapy. Notable elevations of ALT or AST 
(approximately three or more times the upper limit of normal) have been reported 
in approximately 1% of patients in clinical trials with NSAIDs. In addition, 
rare cases of severe hepatic reactions, including jaundice and fatal fulminant 
hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes, 
have been reported.</paragraph>
                  <paragraph>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom 
an abnormal liver test has occurred, should be evaluated for evidence of the 
development of a more severe hepatic reaction while on therapy with etodolac. If 
clinical signs and symptoms consistent with liver disease develop, or if 
systemic manifestations occur (e.g., eosinophilia, rash, etc.), etodolac 
capsules and tablets, USP should be discontinued.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Hematological Effects<paragraph>Anemia is sometimes seen in patients receiving NSAIDs including 
etodolac capsules and tablets, USP. This may be due to fluid retention, occult 
or gross GI blood loss, or an incompletely described effect upon erythropoiesis. 
Patients on long-term treatment with NSAIDs, including etodolac capsules and 
tablets, USP, should have their hemoglobin or hematocrit checked if they exhibit 
any signs or symptoms of anemia.</paragraph>
                  <paragraph>NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding 
time in some patients. Unlike aspirin, their effect on platelet function is 
quantitatively less, of shorter duration, and reversible. Patients receiving 
etodolac capsules and tablets, USP, who may be adversely affected by alterations 
in platelet function, such as those with coagulation disorders or patients 
receiving anticoagulants, should be carefully monitored.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Pre-existing Asthma<paragraph>Patients with asthma may have aspirin-sensitive asthma. The use 
of aspirin in patients with aspirin-sensitive asthmas has been associated with 
severe bronchospasm which can be fatal. Since cross reactivity, including 
bronchospasm, between aspirin and other nonsteroidal anti-inflammatory drugs has 
been reported in such aspirin-sensitive patients, etodolac capsules and tablets, 
USP should not be administered to patients with this form of aspirin sensitivity 
and should be used with caution in all patients with pre-existing asthma.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Information for Patients<paragraph>
                     <content styleCode="bold">Patients should be informed of the following 
information before initiating therapy with an NSAID and periodically during the 
course of ongoing therapy. Patients should also be encouraged to read the NSAID 
Medication Guide that accompanies each prescription dispensed.</content>
                  </paragraph>
                  <list listType="ordered" ID="i027d33f5-27d1-4e97-8df8-d96ca886bacb">
                     <item>Etodolac capsules and tablets, USP, like other NSAIDs, may cause serious CV 
side effects, such as MI or stroke, which may result in hospitalization and even 
death. Although serious CV events can occur without warning symptoms, patients 
should be alert for the signs and symptoms of chest pain, shortness of breath, 
weakness, slurring of speech, and should ask for medical advice when observing 
any indicative sign or symptoms. Patients should be apprised of the importance 
of this follow-up (see <content styleCode="bold">
                           <linkHtml href="#WarnCE">WARNINGS, 
Cardiovascular Effects</linkHtml>
                        </content>).</item>
                     <item>Etodolac capsules and tablets, USP, like other NSAIDs, can cause GI 
discomfort and, rarely, serious GI side effects, such as ulcers and bleeding, 
which may result in hospitalization and even death. Although serious GI tract 
ulcerations and bleeding can occur without warning symptoms, patients should be 
alert for the signs and symptoms of ulcerations and bleeding, and should ask for 
medical advice when observing any indicative sign or symptoms including 
epigastric pain, dyspepsia, melena, and hematemesis. Patients should be apprised 
of the importance of this follow-up (see <content styleCode="bold">
                           <linkHtml href="#WarnGE">WARNINGS, Gastrointestinal Effects - Risk of Ulceration, 
Bleeding, and Perforation</linkHtml>
                        </content>).</item>
                     <item>Etodolac capsules and tablets, USP, like other NSAIDs, can cause serious 
skin side effects such as exfoliative dermatitis, SJS, and TEN, which may result 
in hospitalizations and even death. Although serious skin reactions may occur 
without warning, patients should be alert for the signs and symptoms of skin 
rash and blisters, fever, or other signs of hypersensitivity such as itching, 
and should ask for medical advice when observing any indicative signs or 
symptoms. Patients should be advised to stop the drug immediately if they 
develop any type of rash and contact their physicians as soon as possible.</item>
                     <item>Patients should promptly report signs or symptoms of unexplained weight gain 
or edema to their physicians.</item>
                     <item>Patients should be informed of the warning signs and symptoms of 
hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper 
quadrant tenderness, and "flu-like" symptoms). If these occur, patients should 
be instructed to stop therapy and seek immediate medical therapy.</item>
                     <item>Patients should be informed of the signs of an anaphylactoid reaction (e.g. 
difficulty breathing, swelling of the face or throat). If these occur, patients 
should be instructed to seek immediate emergency help (see <content styleCode="bold">
                           <linkHtml href="#Warnings">WARNINGS</linkHtml>
                        </content>).</item>
                     <item>In late pregnancy, the third trimester, as with other NSAIDs, etodolac 
capsules and tablets, USP should be avoided because they may cause premature 
closure of the ductus arteriosus.</item>
                  </list>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Laboratory Tests<paragraph>Because serious GI tract ulcerations and bleeding can occur 
without warning symptoms, physicians should monitor for signs or symptoms of GI 
bleeding. Patients on long-term treatment with NSAIDs should have their CBC and 
a chemistry profile checked periodically for signs or symptoms of anemia. 
Appropriate measures should be taken in case such signs of anemia occur. If 
clinical signs and symptoms consistent with liver or renal disease develop, 
systemic manifestations occur (e.g., eosinophilia, rash, etc.) or if abnormal 
liver tests persist or worsen, etodolac capsules and tablets, USP should be 
discontinued.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Drug Interactions<linkHtml href=""/>
                  <linkHtml href=""/>ACE-inhibitors<paragraph>Reports suggest that NSAIDs may diminish the antihypertensive 
effect of ACE-inhibitors. This interaction should be given consideration in 
patients taking NSAIDs concomitantly with ACE-inhibitors (see <content styleCode="bold">
                        <linkHtml href="#Warnings">WARNINGS</linkHtml>
                     </content>).</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Antacids<paragraph>The concomitant administration of antacids has no apparent effect 
on the extent of absorption of etodolac capsules and tablets, USP. However, 
antacids can decrease the peak concentration reached by 15% to 20% but have no 
detectable effect on the time-to-peak.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Aspirin<paragraph>When etodolac capsules and tablets, USP is administered with 
aspirin, its protein binding is reduced, although the clearance of free etodolac 
is not altered. The clinical significance of this interaction is not known; 
however, as with other NSAIDs, concomitant administration of etodolac and 
aspirin is not generally recommended because of the potential of increased 
adverse effects.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Cyclosporine, Digoxin, Methotrexate<paragraph>Etodolac, like other NSAIDs, through effects on renal 
prostaglandins, may cause changes in the elimination of these drugs leading to 
elevated serum levels of cyclosporine, digoxin, methotrexate, and increased 
toxicity. Nephrotoxicity associated with cyclosporine may also be enhanced. 
Patients receiving these drugs who are given etodolac, or any other NSAID, and 
particularly those patients with altered renal function, should be observed for 
the development of the specific toxicities of these drugs. NSAIDs, such as 
etodolac, should not be administered prior to or concomitantly with high doses 
of methotrexate. NSAIDs have been reported to competitively inhibit methotrexate 
accumulation in rabbit kidney slices. This may indicate that they could enhance 
the toxicity of methotrexate. In general, caution should be used when NSAIDs are 
administered concomitantly with methotrexate.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Diuretics<paragraph>Etodolac has no apparent pharmacokinetic interaction when 
administered with furosemide or hydrochlorothiazide. Nevertheless, clinical 
studies, as well as postmarketing observations have shown that etodolac can 
reduce the natriuretic effect of furosemide and thiazides in some patients with 
possible loss of blood pressure control. This response has been attributed to 
inhibition of renal prostaglandin synthesis. During concomitant therapy with 
NSAIDs, the patient should be observed closely for signs of renal insufficiency 
or failure (see <content styleCode="bold">
                        <linkHtml href="#WarnRE">WARNINGS, Renal 
Effects</linkHtml>
                     </content>), as well as to assure diuretic efficacy.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Glyburide<paragraph>Etodolac has no apparent pharmacokinetic interaction when 
administered with glyburide.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Lithium<paragraph>NSAIDs have produced an elevation of plasma lithium levels and a 
reduction in renal lithium clearance. The mean minimum lithium concentration 
increased 15% and the renal clearance was decreased by approximately 20%. These 
effects have been attributed to inhibition of renal prostaglandin synthesis by 
the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects 
should be observed carefully for signs of lithium toxicity. Careful monitoring 
of lithium levels is advised in the event NSAID dosage adjustments are 
required.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Phenylbutazone<paragraph>Phenylbutazone causes increase (by about 80%) in the free 
fraction of etodolac. Although <content styleCode="italics">in vivo</content> studies have 
not been done to see if etodolac clearance is changed by coadministration of 
phenylbutazone, it is not recommended that they be coadministered.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Phenytoin<paragraph>Etodolac has no apparent pharmacokinetic interaction when 
administered with phenytoin.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Warfarin<paragraph>The effects of warfarin and NSAIDs on GI bleeding are 
synergistic, such that users of both drugs together have a risk of serious GI 
bleeding higher than that of users of either drug alone. Short-term 
pharmacokinetic studies have demonstrated that concomitant administration of 
warfarin and etodolac capsules and tablets, USP results in reduced protein 
binding of warfarin, but there was no change in the clearance of free warfarin. 
There was no significant difference in the pharmacodynamic effect of warfarin 
administered alone and warfarin administered with etodolac capsules and tablets, 
USP as measured by prothrombin time. Thus, concomitant therapy with warfarin and 
etodolac should not require dosage adjustment of either drug. However, caution 
should be exercised because there have been a few spontaneous reports of 
prolonged prothrombin times, with or without bleeding, in etodolac-treated 
patients receiving concomitant warfarin therapy. Close monitoring of such 
patients is therefore recommended.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Drug/Laboratory Test Interactions<paragraph>The urine of patients who take etodolac can give a false-positive 
reaction for urinary bilirubin (urobilin) due to the presence of phenolic 
metabolites of etodolac. Diagnostic dip-stick methodology, used to detect ketone 
bodies in urine, has resulted in false-positive findings in some patients 
treated with etodolac. Generally, this phenomenon has not been associated with 
other clinically significant events. No dose relationship has been observed.</paragraph>
                  <paragraph>Etodolac treatment is associated with a small decrease in serum uric acid 
levels. In clinical trials, mean decreases of 1 to 2 mg/dL were observed in 
arthritic patients receiving etodolac (600 to 1000 mg/day) after 4 weeks of 
therapy. These levels then remained stable for up to 1 year of therapy.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Carcinogenesis, Mutagenesis, and Impairment of 
Fertility<paragraph>No carcinogenic effect of etodolac was observed in mice or rats 
receiving oral doses of 15 mg/kg/day (45 to 89 mg/m<sup>2</sup>, 
respectively) or less for periods of 2 years or 18 months, respectively. 
Etodolac was not mutagenic in <content styleCode="italics">in vitro</content> tests 
performed with <content styleCode="italics">S. typhimurium</content> and mouse lymphoma 
cells as well as in an <content styleCode="italics">in vivo</content> mouse micronucleus 
test. However, data from the <content styleCode="italics">in vitro</content> human 
peripheral lymphocyte test showed an increase in the number of gaps (3.0 to 5.3% 
unstained regions in the chromatid without dislocation) among the 
etodolac-treated cultures (50 to 200 g/mL) compared to negative controls 
(2.0%); no other difference was noted between the controls and drug-treated 
groups. Etodolac showed no impairment of fertility in male and female rats up to 
oral doses of 16 mg/kg (94 mg/m<sup>2</sup>). However, reduced 
implantation of fertilized eggs occurred in the 8 mg/kg group.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Pregnancy<linkHtml href=""/>
                  <linkHtml href=""/>Teratogenic Effects-Pregnancy Category C<paragraph>In teratology studies, isolated occurrences of alterations in 
limb development were found and included polydactyly, oligodactyly, syndactyly, 
and unossified phalanges in rats and oligodactyly and synostosis of metatarsals 
in rabbits. These were observed at dose levels (2 to 14 mg/kg/day) close to 
human clinical doses. However, the frequency and the dosage group distribution 
of these findings in initial or repeated studies did not establish a clear drug 
or dose-response relationship. Animal reproduction studies are not always 
predictive of human response. There are no adequate and well-controlled studies 
in pregnant women. Etodolac capsules and tablets, USP should be used in 
pregnancy only if the potential benefit justifies the potential risk to the 
fetus.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Nonteratogenic Effects<paragraph>Etodolac capsules and tablets, USP should be used during 
pregnancy only if the potential benefits justify the potential risk to the 
fetus. Because of the known effects of nonsteroidal anti-inflammatory drugs on 
the fetal cardiovascular system (closure of ductus arteriosus), use during 
pregnancy (particularly during the third trimester) should be avoided.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Labor and Delivery<paragraph>In rat studies with NSAIDs, as with other drugs known to inhibit 
prostaglandin synthesis, an increased incidence of dystocia, delayed 
parturition, and decreased pup survival occurred. The effects of etodolac 
capsules and tablets, USP on labor and delivery in pregnant women are 
unknown.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Nursing Mothers<paragraph>Trace amounts of some NSAIDs have been reported in human milk. It 
is not known whether etodalac is excreted in human milk. Because many drugs are 
excreted in human milk and because of the potential for serious adverse 
reactions in nursing infants from etodolac capsules and tablets, USP, a decision 
should be made whether to discontinue nursing or to discontinue the drug taking 
into account the importance of the drug to the mother.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Pediatric Use<paragraph>Safety and effectiveness in pediatric patients below the age of 
18 have not been established.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Geriatric Use<paragraph>As with any NSAID, caution should be exercised in treating the 
elderly (65 years and older) and when increasing the dose (see <content styleCode="bold">
                        <linkHtml href="#Warnings">WARNINGS</linkHtml>
                     </content>).</paragraph>
                  <paragraph>In etodolac capsules and tablets, USP clinical studies, no overall 
differences in safety or effectiveness were observed between these patients and 
younger patients. In pharmacokinetic studies, age was shown not to have any 
effect on etodolac half-life or protein binding, and there was no change in 
expected drug accumulation. Therefore, no dosage adjustment is generally 
necessary in the elderly on the basis of pharmacokinetics (see <content styleCode="bold">
                        <linkHtml href="#CPSP">CLINICAL PHARMACOLOGY, Special 
Populations</linkHtml>
                     </content>).</paragraph>
                  <paragraph>Elderly patients may be more sensitive to the antiprostaglandin effects of 
NSAIDs (on the gastrointestinal tract and kidneys) than younger patients (see 
<content styleCode="bold">
                        <linkHtml href="#Warnings">WARNINGS</linkHtml>
                     </content>). In particular, 
elderly or debilitated patients who receive NSAID therapy seem to tolerate 
gastrointestinal ulceration or bleeding less well than other individuals, and 
most spontaneous reports of fatal GI events are in this population.</paragraph>
                  <paragraph>Etodolac is eliminated primarily by the kidney. Because elderly patients are 
more likely to have decreased renal function, care should be taken in dose 
selection, and it may be useful to monitor renal function (see <content styleCode="bold">
                        <linkHtml href="#WarnRE">WARNINGS, Renal Effects</linkHtml>
                     </content>).</paragraph>
               </text>
               <effectiveTime value="20100407"/>
            </section>
         </component>
         <component>
            <section>
               <id root="d10f5023-5556-4ee0-9f98-a01435595247"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>In patients taking etodolac capsules and tablets, USP or other 
NSAIDs, the most frequently reported adverse experiences occurring in 
approximately 1-10% of patients are:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Gastrointestinal experiences including:</content> abdominal 
pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, 
heartburn, nausea, GI ulcers (gastric/duodenal), vomiting.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Other events including:</content> abnormal renal function, 
anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding 
time, pruritis, rashes, tinnitus.</paragraph>
                  <paragraph>Adverse-reaction information for etodolac was derived from 2,629 arthritic 
patients treated with etodolac capsules and tablets in double-blind and 
open-label clinical trials of 4 to 320 weeks in duration and worldwide 
postmarketing surveillance studies. In clinical trials, most adverse reactions 
were mild and transient. The discontinuation rate in controlled clinical trials, 
because of adverse events, was up to 10% for patients treated with etodolac.</paragraph>
                  <paragraph>New patient complaints (with an incidence greater than or equal to 1%) are 
listed below by body system. The incidences were determined from clinical trials 
involving 465 patients with osteoarthritis treated with 300 to 500 mg of 
etodolac b.i.d. (i.e., 600 to 1000 mg/day).</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Incidence Greater Than Or Equal To 1% - Probably 
Causally Related<paragraph>Body as a whole - Chills and fever.<br/>Digestive system - 
Dyspepsia (10%), abdominal pain<linkHtml href="#footnote-3">1</linkHtml>, diarrhea<linkHtml href="#footnote-3">1</linkHtml>, 
flatulence<linkHtml href="#footnote-3">1</linkHtml>, nausea<linkHtml href="#footnote-3">1</linkHtml>, abdominal distension, epigastric pain, abnormal 
stools, constipation, gastritis, melena, vomiting.<br/>Nervous system - 
Asthenia/malaise<linkHtml href="#footnote-3">1</linkHtml>, dizziness<linkHtml href="#footnote-3">1</linkHtml>, depression, nervousness, fatigue.<br/>Skin and 
appendages - Pruritus, rash.<br/>Special senses - Blurred vision, 
tinnitus.<br/>Urogenital system - Dysuria, urinary 
frequency.<br/>MusculoskeletalArthralgia.</paragraph>
                  <paragraph>Drug-related patient complaints occurring in fewer than 3%, but more than 1%, 
are unmarked.</paragraph>
                  <linkHtml href="#footnote-reference-3">1</linkHtml>Drug-related patient complaints occurring in 3 to 9% of patients treated 
with etodolac.<linkHtml href=""/>
                  <linkHtml href=""/>Incidence Less Than 1% - Probably Causally 
Related<paragraph>(Adverse reactions reported only in worldwide postmarketing 
experience, not seen in clinical trials, are considered rarer and are 
italicized.)</paragraph>
                  <paragraph>Body as a whole - <content styleCode="italics">Allergic reaction, 
anaphylactic/anaphylactoid reactions (including shock).</content>
                     <br/>Cardiovascular system - Hypertension, congestive heart failure, flushing, 
palpitations, syncope, <content styleCode="italics">vasculitis (including necrotizing and 
allergic).</content>
                     <br/>Digestive system - Thirst, dry mouth, ulcerative 
stomatitis, anorexia, eructation, elevated liver enzymes, <content styleCode="italics">cholestatic hepatitis,</content> hepatitis, <content styleCode="italics">cholestatic jaundice, duodenitis, jaundice, hepatic failure, liver 
necrosis,</content> peptic ulcer with or without bleeding and/or perforation, <content styleCode="italics">intestinal ulceration, pancreatitis.</content>
                     <br/>Hemic and 
lymphatic system - Ecchymosis, anemia, thrombocytopenia, bleeding time 
increased, <content styleCode="italics">agranulocytosis, hemolytic anemia, aplastic 
anemia, leukopenia, neutropenia, pancytopenia.</content>
                     <br/>Metabolic and 
nutritional - Edema, serum creatinine increase, <content styleCode="italics">hyperglycemia in previously controlled diabetic patients.</content>
                     <br/>Nervous system - Insomnia, somnolence.<br/>Respiratory system - Asthma, <content styleCode="italics">pulmonary infiltration with eosinophilia</content>.<br/>Skin and 
appendages - Angioedema, sweating, urticaria, exfoliative dermatitis, 
vesiculobullous rash, <content styleCode="italics">cutaneous vasculitis with purpura, 
Stevens-Johnson Syndrome, toxic epidermal necrolysis, leukocytoclastic 
vasculitis,</content> hyperpigmentation<content styleCode="italics">, erythema 
multiforme.</content>
                     <br/>Special senses - Photophobia, transient visual 
disturbances.<br/>Urogenital system - <content styleCode="italics">Elevated BUN, renal 
failure, renal insufficiency, renal papillary necrosis.</content>
                  </paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Incidence Less Than 1% - Causal Relationship 
Unknown<paragraph>(Medical events occurring under circumstances where causal 
relationship to etodolac is uncertain. These reactions are listed as alerting 
information for physicians.)</paragraph>
                  <paragraph>Body as a whole - Infection, headache.<br/>Cardiovascular system - 
Arrhythmias, myocardial infarction, cerebrovascular accident.<br/>Digestive 
system - Esophagitis with or without stricture or cardiospasm, colitis, GI 
discomfort, burning sensation, blood in stools, gastralgia, upper abdominal 
discomfort.<br/>Metabolic and nutritional - Change in weight.<br/>Nervous system - 
Paresthesia, confusion, irritability.<br/>Respiratory system - Bronchitis, 
bronchospasm, dyspnea, pharyngitis, rhinitis, sinusitis.<br/>Skin and appendages 
- Alopecia, maculopapular rash, photosensitivity, skin peeling.<br/>Special 
senses - Conjunctivitis, deafness, taste perversion, loss of 
taste.<br/>Urogenital system - Cystitis, hematuria, leukorrhea, renal calculus, 
interstitial nephritis, uterine bleeding irregularities, renal 
impairment.<br/>MusculoskeletalMuscle pain.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Additional Adverse Reactions Reported with 
NSAIDs<paragraph>Body as a whole - Sepsis, death<br/>Cardiovascular system - 
Tachycardia<br/>Digestive system - Gastric ulcers, gastritis, gastrointestinal 
bleeding, glossitis, hematemesis<br/>Hemic and lymphatic system - 
Lymphadenopathy<br/>Nervous system - Anxiety, dream abnormalities, convulsions, 
coma, hallucinations, meningitis, tremors, vertigo<br/>Respiratory system - 
Respiratory depression, pneumonia<br/>Urogenital system - Oliguria/polyuria, 
proteinuria</paragraph>
               </text>
               <effectiveTime value="20100407"/>
            </section>
         </component>
         <component>
            <section>
               <id root="959fd3d2-d059-4a7e-9e81-ffdb738186e3"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Symptoms following acute NSAID overdose are usually limited to 
lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally 
reversible with supportive care. Gastrointestinal bleeding can occur and coma 
has occurred following massive ibuprofen or mefenamic-acid overdose. 
Hypertension, acute renal failure, and respiratory depression may occur but are 
rare. Anaphylactoid reactions have been reported with therapeutic ingestion of 
NSAIDs, and may occur following overdose.</paragraph>
                  <paragraph>Patients should be managed by symptomatic and supportive care following an 
NSAID overdose. There are no specific antidotes. Emesis and/or activated 
charcoal (60 to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic 
cathartic may be indicated in patients seen within 4 hours of ingestion with 
symptoms or following a large overdose (5 to 10 times the usual dose). Forced 
diuresis, alkalinization of the urine, hemodialysis, or hemoperfusion would 
probably not be useful due to etodolac's high protein binding.</paragraph>
               </text>
               <effectiveTime value="20100407"/>
            </section>
         </component>
         <component>
            <section>
               <id root="110247c6-d385-4d3b-b039-b39186574751"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Carefully consider the potential benefits and risks of etodolac 
capsules and tablets, USP and other treatment options before deciding to use 
etodolac capsules and tablets, USP. Use the lowest effective dose for the 
shortest duration consistent with individual patient treatment goals (see <content styleCode="bold">
                        <linkHtml href="#Warnings">WARNINGS</linkHtml>
                     </content>).</paragraph>
                  <paragraph>After observing the response to initial therapy with etodolac capsules and 
tablets, USP, the dose and frequency should be adjusted to suit an individual 
patient's needs.</paragraph>
                  <paragraph>Dosage adjustment of etodolac capsules and tablets, USP is generally not 
required in patients with mild to moderate renal impairment. Etodolac should be 
used with caution in such patients, because, as with other NSAIDs, it may 
further decrease renal function in some patients with impaired renal function 
(see <content styleCode="bold">
                        <linkHtml href="#WarnRE">WARNINGS, Renal 
Effects</linkHtml>
                     </content>).</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Analgesia<paragraph>The recommended total daily dose of etodolac for acute pain is up 
to 1000 mg, given as 200-400 mg every 6 to 8 hours. Doses of etodolac greater 
than 1000 mg/day have not been adequately evaluated in well-controlled 
trials.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Osteoarthritis and Rheumatoid Arthritis<paragraph>The recommended starting dose of etodolac for the management of 
the signs and symptoms of osteoarthritis or rheumatoid arthritis is: 300 mg 
b.i.d., t.i.d., or 400 mg b.i.d., or 500 mg b.i.d. A lower dose of 600 mg/day 
may suffice for long-term administration. Physicians should be aware that doses 
above 1000 mg/day have not been adequately evaluated in well-controlled clinical 
trials.</paragraph>
                  <paragraph>In chronic conditions, a therapeutic response to therapy with etodolac is 
sometimes seen within one week of therapy, but most often is observed by two 
weeks. After a satisfactory response has been achieved, the patient's dose 
should be reviewed and adjusted as required.</paragraph>
               </text>
               <effectiveTime value="20100407"/>
            </section>
         </component>
         <component>
            <section>
               <id root="5dc1c25f-3a9e-4144-bd44-1eab55319794"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Etodolac Capsules and Tablets, USP are available as:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Etodolac Capsules, USP</content>
                  </paragraph>
                  <paragraph>200 mg capsules (pink capsules with "ETO 200 MG" imprinted in black on cap 
and body), supplied in<br/>
                  </paragraph>
                  <table width="30%" ID="ia13f3cce-d052-41f7-86a3-0ff3aab26562">
                     <tbody>
                        <tr>
                           <td>Bottles of 20<br/>
                           </td>
                           <td>NDC 54868-5274-1<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Bottles of 30<br/>
                           </td>
                           <td>NDC 54868-5274-2<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Bottles of 60<br/>
                           </td>
                           <td>NDC 54868-5274-0<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Bottles of 90<br/>
                           </td>
                           <td>NDC 54868-5274-3<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>300 mg capsules (light pink capsules with "ETO 300 MG" imprinted in black on 
cap and body), supplied in<br/>
                  <table width="30%" ID="ia5976696-e29f-417f-824e-edee17dbaaac">
                     <tbody>
                        <tr>
                           <td>Bottles of 10<br/>
                           </td>
                           <td>NDC 54868-4135-1<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Bottles of 60<br/>
                           </td>
                           <td>NDC 54868-4135-0<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">Store at 20-25C (68-77F)</content> [see USP 
Controlled Room Temperature], <content styleCode="bold">protected from 
moisture</content>.<linkHtml href="#section-"/>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">- - - - - - - - - </content>
                     <content styleCode="bold">- - - - - - - - - </content>
                     <content styleCode="bold">- - - - - - - - - </content>
                     <content styleCode="bold">- - - - - - - - - </content>
                     <content styleCode="bold">- - - - - - - - - </content>
                     <content styleCode="bold">- - - - - - - - - </content>
                     <content styleCode="bold">- - - - - - - - - </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Etodolac Tablets, USP</content>
                  </paragraph>
                  <paragraph>400 mg tablets (peach, oval shape, film coated, unscored tablet with "T88" 
engraved on one side), supplied in<br/>
                  </paragraph>
                  <table width="30%" ID="ida3fdca0-2637-4fc1-8e64-7060d6674bdf">
                     <tbody>
                        <tr>
                           <td>Bottles of 30<br/>
                           </td>
                           <td>NDC 54868-3955-0<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Bottles of 60<br/>
                           </td>
                           <td>NDC 54868-3955-1<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Bottles of 90<br/>
                           </td>
                           <td>NDC 54868-3955-2<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Bottles of 100<br/>
                           </td>
                           <td>NDC 54868-3955-4<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Bottles of 120<br/>
                           </td>
                           <td>NDC 54868-3955-3<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>500 mg tablets (blue, oval shape, film coated, unscored tablet with "TARO" 
engraved on one side and "89." engraved on the other side), supplied in<br/>
                  </paragraph>
                  <table width="30%" ID="ib52e1f92-6a31-4c10-8799-93ed68f0a43f">
                     <tbody>
                        <tr>
                           <td>Bottles of 10<br/>
                           </td>
                           <td>NDC 54868-4059-0<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Bottles of 15<br/>
                           </td>
                           <td>NDC 54868-4059-1<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Bottles of 60<br/>
                           </td>
                           <td>NDC 54868-4059-3<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Bottles of 100<br/>
                           </td>
                           <td>NDC 54868-4059-2<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Store at 20-25C (68-77F)</content> [see USP 
Controlled Room Temperature]. <content styleCode="bold">Store tablets in original 
container until ready to use. Dispense in light-resistant container.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20110316"/>
            </section>
         </component>
         <component>
            <section>
               <id root="3180881e-08f9-4439-a83f-dada123102f1"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <linkHtml href=""/>Medication Guide for Non-Steroidal Anti-Inflammatory 
Drugs (NSAIDs)<paragraph>
                     <content styleCode="underline">(See the end of this Medication Guide for a 
list of prescription NSAID medicines.)</content>
                  </paragraph>
                  <table width="100%" ID="i5ad49557-16c5-4c36-850b-a2a18c0218e6">
                     <col width="100%"/>
                     <tbody>
                        <tr>
                           <td>
                              <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about 
medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NSAID medicines may increase the chance of a heart attack or 
stroke that can lead to death.</content> This chance increases:</paragraph>
                  <list listType="unordered" ID="ia3f55e31-2159-44db-8a25-cf17f78296f5">
                     <item>with longer use of NSAID medicines</item>
                     <item>in people who have heart disease</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">NSAID medicines should never be used right before or after a 
heart surgery called a "coronary artery bypass graft (CABG)."</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NSAID medicines can cause ulcers and bleeding in the stomach 
and intestines at any time during treatment. Ulcers and bleeding:</content>
                  </paragraph>
                  <list listType="unordered" ID="ifb931f18-4bd4-4455-87bd-7a1d7def73ad">
                     <item>can happen without warning symptoms</item>
                     <item>may cause death<br/>
                        <content styleCode="bold">The chance of a person getting an ulcer 
or bleeding increases with:</content>
                        <list listType="unordered" ID="idee7af12-1b39-4500-82c0-37ade000efec">
                           <item>taking medicines called "corticosteroids" and "anticoagulants"</item>
                           <item>longer use</item>
                           <item>smoking</item>
                           <item>drinking alcohol</item>
                           <item>older age</item>
                           <item>having poor health</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">NSAID medicines should only be used:</content>
                  </paragraph>
                  <list listType="unordered" ID="i4214b2d6-a06f-4d8c-8c5a-da7006bcf7bd">
                     <item>exactly as prescribed</item>
                     <item>at the lowest dose possible for your treatment</item>
                     <item>for the shortest time needed</item>
                  </list>
                  <table width="100%" ID="i33b3f964-3493-42c7-82a9-78baa08cbe70">
                     <col width="100%"/>
                     <tbody>
                        <tr>
                           <td>
                              <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">What are Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs)?</content>
                  </paragraph>
                  <paragraph>NSAID medicines are used to treat pain and redness, swelling, and heat 
(inflammation) from medical conditions such as:</paragraph>
                  <list listType="unordered" ID="i7d063194-6bb8-4a8e-8051-f715928165d6">
                     <item>different types of arthritis</item>
                     <item>menstrual cramps and other types of short-term pain</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Who should not take a Non-Steroidal Anti-Inflammatory Drug 
(NSAID)?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take an NSAID medicine:</content>
                  </paragraph>
                  <list listType="unordered" ID="ie79b18f6-de7a-46c2-82de-31ae755c675e">
                     <item>if you had an asthma attack, hives, or other allergic reaction with aspirin 
or any other NSAID medicine</item>
                     <item>for pain right before or after heart bypass surgery</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider:</content>
                  </paragraph>
                  <list listType="unordered" ID="icba9d1e4-4ced-43cd-8c15-99932ee06912">
                     <item>about all of your medical conditions.</item>
                     <item>about all of the medicines you take. NSAIDs and some other medicines can 
interact with each other and cause serious side effects. <content styleCode="bold">Keep a 
list of your medicines to show to your healthcare provider and 
pharmacist.</content>
                     </item>
                     <item>if you are pregnant. <content styleCode="bold">NSAID medicines should not be used by 
pregnant women late in their pregnancy.</content>
                     </item>
                     <item>if you are breastfeeding. <content styleCode="bold">Talk to your doctor.</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of Non-Steroidal 
Anti-Inflammatory Drugs (NSAIDs)?</content>
                  </paragraph>
                  <table width="80%" ID="i17d54304-65b2-430a-841d-8c169152f611">
                     <col align="left" valign="top" width="60%"/>
                     <col align="left" valign="top" width="40%"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Serious side effects 
include:</content>
                           </td>
                           <td>
                              <content styleCode="bold">Other side effects 
include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <list listType="unordered" ID="i6652e5a3-736e-42fd-8f74-167767559a45">
                                 <item>heart attack</item>
                                 <item>stroke</item>
                                 <item>high blood pressure</item>
                                 <item>heart failure from body swelling (fluid retention)</item>
                                 <item>kidney problems including kidney failure</item>
                                 <item>bleeding and ulcers in the stomach and intestine</item>
                                 <item>low red blood cells (anemia)</item>
                                 <item>life-threatening skin reactions</item>
                                 <item>life-threatening allergic reactions</item>
                                 <item>liver problems including liver failure</item>
                                 <item>asthma attacks in people who have asthma</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" ID="iae53b11c-b977-4cd6-8e54-e39bc26afbe2">
                                 <item>stomach pain</item>
                                 <item>constipation</item>
                                 <item>diarrhea</item>
                                 <item>gas</item>
                                 <item>heartburn</item>
                                 <item>nausea</item>
                                 <item>vomiting</item>
                                 <item>dizziness</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Get emergency help right away if you have any of the 
following symptoms:</content>
                  </paragraph>
                  <table width="80%" ID="i92e72873-dd91-42b7-8418-e6cd5fbf74f6">
                     <col align="left" valign="top" width="60%"/>
                     <col align="left" valign="top" width="40%"/>
                     <tbody>
                        <tr>
                           <td>
                              <list listType="unordered" ID="id94b2a0a-3a82-4b53-8c6f-1eafe3c901d4">
                                 <item>shortness of breath or trouble breathing</item>
                                 <item>chest pain</item>
                                 <item>weakness in one part or side of your body</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" ID="i2622b3c8-9353-40ad-8da7-61b1ca27c362">
                                 <item>slurred speech</item>
                                 <item>swelling of the face or throat</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Stop your NSAID medicine and call your healthcare provider 
right away if you have any of the following symptoms:</content>
                  </paragraph>
                  <table width="80%" ID="iad0cf633-f2d6-4a1e-80dc-d9c1e7b56cc4">
                     <col align="left" valign="top" width="50%"/>
                     <col align="left" valign="top" width="50%"/>
                     <tbody>
                        <tr>
                           <td>
                              <list listType="unordered" ID="i470d0346-0075-4044-8cc8-715cd7caba40">
                                 <item>nausea</item>
                                 <item>more tired or weaker than usual</item>
                                 <item>itching</item>
                                 <item>your skin or eyes look yellow</item>
                                 <item>stomach pain</item>
                                 <item>flu-like symptoms</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" ID="ie1cd13f6-70dc-481c-8af4-f88c19841628">
                                 <item>vomit blood</item>
                                 <item>there is blood in your bowel movement or it is black and sticky like 
tar</item>
                                 <item>unusual weight gain</item>
                                 <item>skin rash or blisters with fever</item>
                                 <item>swelling of the arms and legs, hands and 
feet</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>These are not all the side effects with NSAID medicines. Talk to your 
healthcare provider or pharmacist for more information about NSAID 
medicines.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Other information about Non-Steroidal Anti-Inflammatory 
Drugs (NSAIDs)</content>
                  </paragraph>
                  <list listType="unordered" ID="i01372aeb-ce01-47cf-8fe4-554b9fa19986">
                     <item>Aspirin is an NSAID medicine but it does not increase the chance of a heart 
attack. Aspirin can cause bleeding in the brain, stomach, and intestines. 
Aspirin can also cause ulcers in the stomach and intestines.</item>
                     <item>Some of these NSAID medicines are sold in lower doses without a prescription 
(overthecounter). Talk to your healthcare provider before using 
overthecounter NSAIDs for more than 10 days.</item>
                  </list>
                  <paragraph>
                     <content>NSAID medicines that need a prescription</content>
                  </paragraph>
                  <table width="100%" ID="ifc38b4d5-72cd-4db2-8cc2-eaee768d8e58">
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Generic Name</content>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Tradename</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Celecoxib<br/>
                           </td>
                           <td>Celebrex<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Diclofenac<br/>
                           </td>
                           <td>Cataflam, Voltaren, Arthrotec (combined with 
misoprostol)</td>
                        </tr>
                        <tr>
                           <td>Diflunisal<br/>
                           </td>
                           <td>Dolobid<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Etodolac<br/>
                           </td>
                           <td>Lodine, Lodine XL<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Fenoprofen<br/>
                           </td>
                           <td>Nalfon, Nalfon 200<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Flurbirofen<br/>
                           </td>
                           <td>Ansaid<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Ibuprofen<br/>
                           </td>
                           <td>Motrin, Tab-Profen, Vicoprofen<linkHtml href="SPLForm_DrugListing.xhtml#footnote-4">*</linkHtml> (combined with hydrocodone), 
Combunox (combined with oxycodone)</td>
                        </tr>
                        <tr>
                           <td>Indomethacin<br/>
                           </td>
                           <td>Indocin, Indocin SR, Indo-Lemmon, 
Indomethagan</td>
                        </tr>
                        <tr>
                           <td>Ketoprofen<br/>
                           </td>
                           <td>Oruvail<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Ketorolac<br/>
                           </td>
                           <td>Toradol<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Mefenamic Acid<br/>
                           </td>
                           <td>Ponstel<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Meloxicam<br/>
                           </td>
                           <td>Mobic<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Nabumetone<br/>
                           </td>
                           <td>Relafen<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Naproxen<br/>
                           </td>
                           <td>Naprosyn, Anaprox, Anaprox DS, EC-Naproxyn, Naprelan, 
Naprapac (copackaged with lansoprazole)</td>
                        </tr>
                        <tr>
                           <td>Oxaprozin<br/>
                           </td>
                           <td>Daypro<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Piroxicam<br/>
                           </td>
                           <td>Feldene<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Sulindac<br/>
                           </td>
                           <td>Clinoril<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Tolmetin<br/>
                           </td>
                           <td>Tolectin, Tolectin DS, Tolectin 600<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <linkHtml href="SPLForm_DrugListing.xhtml#footnote-4">*</linkHtml> Vicoprofen contains the same dose of ibuprofen as over-the-counter (OTC) 
NSAIDs, and is usually used for less than 10 days to treat pain. The OTC label 
warns that long term continuous use may increase the risk of heart attack or 
stroke.<br/>
                     <content/>
                  </paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Call your doctor for medical advice about side effects. You 
may report side effects to FDA at 1-800-FDA-1088.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">This Medication Guide has been approved by the U.S. Food 
and Drug Administration. </content>
                  </paragraph>
                  <linkHtml href=""/>
                  <paragraph>Manufactured by: Taro Pharmaceutical Industries Ltd., Haifa Bay, 
Israel 26110<br/>Distributed by: <content styleCode="bold">Taro Pharmaceuticals U.S.A., 
Inc.</content>, Hawthorne, NY 10532</paragraph>
                  <paragraph>Revised: December, 2008</paragraph>
                  <br/>
                  <paragraph/>
               </text>
               <effectiveTime value="20100407"/>
            </section>
         </component>
         <component>
            <section>
               <id root="556e64a7-36e2-4f4e-89c6-e5fcb794c4b9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Etodolac Capsules, USP</content>
                  </paragraph>
                  <paragraph>200 mg capsules</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM2"/>
                  </paragraph>300 mg capsules<renderMultiMedia referencedObject="MM3"/>
                  <linkHtml href=""/>
                  <paragraph>
                     <content styleCode="bold"/>
                     <br/>
                  </paragraph>
                  <linkHtml href=""/>
                  <paragraph>
                     <content styleCode="bold">Etodolac Tablets, USP</content>
                  </paragraph>
                  <paragraph>400 mg tablets</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM4"/>
                  </paragraph>
                  <paragraph>500 mg tablets</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM5"/>
                  </paragraph>
               </text>
               <effectiveTime value="20100407"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM2">
                     <text>image of 200 mg package label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="200mg package label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM3">
                     <text>image of 300 mg package label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="300mg package label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM4">
                     <text>image of 400 mg package label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="400mg package label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM5">
                     <text>image of 500 mg package label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="500mg package label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>